Target intelligence / Profile preview

Gastric epithelial glycolipid receptors

Molecular classification
Glycolipid, Receptor, Glycan-based receptor
01

Overview

Gastric epithelial glycolipid receptors are a diverse group of carbohydrate-containing lipids located on the apical surface of the gastric mucosa that serve as critical attachment sites for pathogens. These receptors include neutral glycolipids such as Lewis b (Leb) and H-type 1 antigens, as well as acidic glycolipids like sulfatides and sialyl-Lewis x (sLex) (Borén et al., 1993; Saitoh et al., 1991). Their primary biological function in the context of human disease is to facilitate the adhesion of Helicobacter pylori via bacterial adhesins like BabA and SabA, which is a prerequisite for persistent colonization and subsequent mucosal injury (Mahdavi et al., 2002). This interaction is a key driver in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric malignancies, including adenocarcinoma and MALT lymphoma. Therapeutic interventions targeting these receptors focus on anti-adhesive strategies, such as the use of carbohydrate mimetics or competitive inhibitors like 3'-sialyllactose to prevent bacterial docking (Simon et al., 1997). Additionally, gastroprotective agents like rebamipide have been shown to modulate the composition and protective function of these glycolipids, enhancing the gastric mucosal barrier against injury (Naito et al., 2010).

Other names
Gastric mucosal glycolipidsLewis blood group antigensSialylated gastric glycolipidsSulfatidesH-type 1 antigens
02

Mechanism of action

Inhibition of bacterial adhesion to the gastric mucosa through competitive binding or modulation of receptor expression.

03

Biological functions

Pathogen adhesionCell-cell recognitionMucosal barrier maintenanceSignal transduction
04

Disease associations

Helicobacter pylori infectionGastritisPeptic ulcer diseaseGastric adenocarcinomaMALT lymphoma
05

Safety considerations

Potential disruption of normal gastric microbiotaAlteration of mucosal protective layersLow bioavailability of carbohydrate-based inhibitors
06

Interacting drugs

Rebamipide

3 more in the full profile.

07

Biomarkers

Lewis antigen phenotypeSecretor status (FUT2)Sialyl-Lewis x expression

Beyond the preview

Go deeper on Gastric epithelial glycolipid receptors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric epithelial glycolipid receptors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call